Skip to content
10-Q

Quarterly Report

ARCUTIS BIOTHERAPEUTICS, INC. ARQT

0001787306-24-000153

← back to feed
Filed
Nov 6, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 1, 2024 117.04M sh
Long Term Debt Q3 2024 · Sep 30, 2024 $105.1M
Long Term Debt Q3 2024 · Dec 31, 2023 $201.8M
Short Term Debt Q3 2024 · Sep 30, 2024 $99.51M
Short Term Debt Q3 2024 · Dec 31, 2023 $0
Cash And Equivalents Q3 2024 · Sep 30, 2024 $134.85M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $88.4M
Current Liabilities Q3 2024 · Sep 30, 2024 $172.43M
Current Liabilities Q3 2024 · Dec 31, 2023 $46.67M
Total Liabilities Q3 2024 · Sep 30, 2024 $280.71M
Total Liabilities Q3 2024 · Dec 31, 2023 $252.7M
Current Assets Q3 2024 · Sep 30, 2024 $423.72M
Current Assets Q3 2024 · Dec 31, 2023 $330.43M
Total Assets Q3 2024 · Sep 30, 2024 $437.35M
Total Assets Q3 2024 · Dec 31, 2023 $341.37M
Shares Diluted Q3 2024 · Sep 30, 2023 61.73M sh
Shares Diluted Q3 2024 · Sep 30, 2023 61.46M sh
Capex Q3 2024 · Sep 30, 2023 $422K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$190.81M
Stockholders Equity Q3 2024 · Sep 30, 2023 $46.72M
Stockholders Equity Q3 2024 · Jun 30, 2023 $80.51M
Stockholders Equity Q3 2024 · Mar 31, 2023 $139.73M
Stockholders Equity Q3 2024 · Dec 31, 2022 $209.58M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.73
Eps Diluted Q3 2024 · Sep 30, 2023 −$3.19
Eps Basic Q3 2024 · Sep 30, 2023 −$0.73
Eps Basic Q3 2024 · Sep 30, 2023 −$3.19
Sga Expense Q3 2024 · Sep 30, 2023 $47.6M
Sga Expense Q3 2024 · Sep 30, 2023 $136.47M
Rd Expense Q3 2024 · Sep 30, 2023 $26.24M
Rd Expense Q3 2024 · Sep 30, 2023 $86.8M
Net Income Q3 2024 · Sep 30, 2023 −$44.77M
Net Income Q3 2024 · Sep 30, 2023 −$195.86M
Net Income Q3 2024 · Jun 30, 2023 −$70.99M
Net Income Q3 2024 · Mar 31, 2023 −$80.1M
Operating Income Q3 2024 · Sep 30, 2023 −$36.9M
Operating Income Q3 2024 · Sep 30, 2023 −$179.93M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $1.18M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $2.74M
Revenue Q3 2024 · Sep 30, 2023 $38.11M
Revenue Q3 2024 · Sep 30, 2023 $46.08M